68Ga-OPS202在胃肠胰神经内分泌肿瘤患者中的安全性、生物分布与辐射剂量学:一项前瞻性Ⅰ期显像研究
这项前瞻性Ⅰ期研究纳入12例高分化胃肠胰神经内分泌肿瘤患者,间隔3–4周接受两次150 MBq的68Ga-OPS202静脉注射(第1次15 μg肽、第2次50 μg),评估安全性、生物分布、辐射剂量学及最佳显像时间。结果显示血液清除快,平均停留时间2.4±1.1 min/L,有效剂量2.4E-02±0.2E-02 mSv/MBq(参考活度150 MBq对应3.6 mSv),最佳肿瘤对比时间为注射后1–2 h,药物耐受良好。
要点
- 12例高分化胃肠胰神经内分泌肿瘤患者完成两次150 MBq的68Ga-OPS202注射,安全性良好,不良事件为1–2级。
- 有效剂量为2.4E-02±0.2E-02 mSv/MBq,参考活度150 MBq对应3.6 mSv。
- 基于检出恶性病灶总数,最佳显像时间窗为注射后1–2 h;肝恶性病灶多数患者最高平均肿瘤对比时间为1 h。
核心结论
- 68Ga-OPS202显示出良好的生物分布和显像特性,注射后1–2 h肿瘤对比最佳;剂量学分析显示其向器官递送的剂量与其他68Ga标记的生长抑素受体类似物相似,因此值得进一步评估68Ga-OPS202用于神经内分泌肿瘤PET/CT显像。
研究设计与样本
- 前瞻性Ⅰ/Ⅱ期研究,此处报告Ⅰ期结果;患者间隔3–4周接受两次单次150 MBq的68Ga-OPS202静脉注射(第1次15 μg肽,第2次50 μg)。
- 第1次访视行动态肾脏PET/CT(注射后前30 min)及注射后0.5、1、2、4 h静态全身扫描;第2次访视行注射后1 h静态全身扫描。
- 定期采集血样和尿液测定68Ga-OPS202药代动力学,评估安全性、生物分布、辐射剂量学及最适显像时间点。
- 共12例高分化胃肠胰神经内分泌肿瘤患者参与研究。
主要发现
- 68Ga-OPS202从血液中快速清除,平均停留时间为2.4±1.1 min/L。
- 平均剂量系数最高的器官为膀胱壁、肾脏和脾脏。
- 计算的有效剂量为2.4E-02±0.2E-02 mSv/MBq,参考活度150 MBq时对应3.6 mSv。
- 基于检出的恶性病灶总数,最佳扫描时间窗为1–2 h;对于肝恶性病灶,多数患者平均肿瘤对比最高的时间点为1 h。
- 68Ga-OPS202耐受良好,不良事件为1级或2级,实验室血液或尿液分析检查无令人担忧的信号。
关键数值与推荐
- 计算的有效剂量为2.4E-02±0.2E-02 mSv/MBq,参考活度150 MBq对应3.6 mSv。
- 68Ga-OPS202从血液中快速清除,平均停留时间为2.4±1.1 min/L。
- 基于检出恶性病灶总数,最佳扫描时间窗为1–2 h;肝恶性病灶多数患者最高平均肿瘤对比时间为1 h。
- 不良事件为1级或2级,实验室血液或尿液分析无令人担忧的信号。
临床怎么用
- 作者认为68Ga-OPS202具有良好的生物分布和显像特性,注射后1–2 h肿瘤对比最佳,值得进一步评估其用于神经内分泌肿瘤PET/CT显像。
局限性
- 原文结论指出因此值得进一步评估68Ga-OPS202用于神经内分泌肿瘤PET/CT显像。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Preclinical and preliminary clinical evidence indicates that radiolabeled somatostatin (sst) receptor antagonists perform better than agonists in detecting neuroendocrine tumors (NETs). We performed a prospective phase I/II study to evaluate the sst receptor antagonist 68Ga-OPS202 (68Ga-NODAGA-JR11; NODAGA = 1,4,7-triazacyclononane,1-glutaric acid-4,7-acetic acid and JR11 = Cpa-c(dCys-Aph(Hor)-dAph(Cbm)-Lys-Thr-Cys)-dTyr-NH2)) for PET imaging. Here, we report the results of phase I of the study. Methods: Patients received 2 single 150-MBq intravenous injections of 68Ga-OPS202 3-4 wk apart (15 μg of peptide at visit 1 and 50 μg at visit 2). At visit 1, a dynamic PET/CT scan over the kidney was obtained during the first 30 min after injection, and static whole-body scans were obtained at 0.5, 1, 2, and 4 h after injection; at visit 2, a static whole-body scan was obtained at 1 h. Blood samples and urine were collected at regular intervals to determine 68Ga-OPS202 pharmacokinetics. Safety, biodistribution, radiation dosimetry, and the most appropriate imaging time point for 68Ga-OPS202 were assessed. Results: Twelve patients with well-differentiated gastroenteropancreatic (GEP) NETs took part in the study. 68Ga-OPS202 cleared rapidly from the blood, with a mean residence time of 2.4 ± 1.1 min/L. The organs with the highest mean dose coefficients were the urinary bladder wall, kidneys, and spleen. The calculated effective dose was 2.4E-02 ± 0.2E-02 mSv/MBq, corresponding to 3.6 mSv, for a reference activity of 150 MBq. Based on total numbers of detected malignant lesions, the optimal time window for the scan was between 1 and 2 h. For malignant liver lesions, the time point at which most patients had the highest mean tumor contrast was 1 h. 68Ga-OPS202 was well tolerated; adverse events were grade 1 or 2, and there were no signals of concern from laboratory blood or urinalysis tests. Conclusion:68Ga-OPS202 showed favorable biodistribution and imaging properties, with optimal tumor contrast between 1 and 2 h after injection. Dosimetry analysis revealed that the dose delivered by 68Ga-OPS202 to organs is similar to that delivered by other 68Ga-labeled sst analogs. Further evaluation of 68Ga-OPS202 for PET/CT imaging of NETs is therefore warranted.
引用
- Nicolas GP, Beykan S, Bouterfa H, et al. Safety, Biodistribution, and Radiation Dosimetry of 68Ga-OPS202 in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase I Imaging Study. J Nucl Med. 2017. PMID: 29025985. doi:10.2967/jnumed.117.199737
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。